A Oneindia Venture
Get Updates
Get notified about market trends, financial advice, and investment tips!
Click it and Unblock the Notifications
Nippon India Pharma Fund
Regular
Direct
3 Year Absolute Returns
39.46% ↑
NAV (₹) on 02 Apr 2026
104.79
1 Day NAV Change
-0.56%
Risk Level
Very High Risk
Rating
-
Nippon India Pharma Fund is a Equity mutual fund categorized under Sector, offered by Nippon Life India Asset Management Ltd.. Launched on 05 Jun 2004, investors can start with a minimum SIP of ₹100 ... Read more
NAV History
Fund Details
Min. SIP Amount
₹100
Inception Date
05 Jun 2004
Min. Lumpsum Amount
₹ 5,000
Fund Age
21 Yrs
AUM
₹ 8,306.35 Cr.
Benchmark
BSE Healthcare Total Return
Expense Ratio
1.81%
Scheme Type
Open Ended
Exit Load
1%
Returns Calculator
Investment amount per month
₹1,000
Over the past
Would have become
On total investment of
*Calculation based on past performance of this fund.
Asset Allocation
AUM
₹ 8,306.35 Cr
Equity
198.28%
Money Market & Cash
1.86%
Sector Holdings
| Sectors | Weightage |
|---|---|
| Pharmaceuticals | 77.91% |
| Hospitals & Medical Services | 20.62% |
| Chemicals - Speciality | 1.15% |
| Treps/Reverse Repo | 0.34% |
Stock Holdings
| Name | Weightage | Value (in Cr.) | Sector |
|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 13.08% | ₹ 1,086.73 | Pharmaceuticals |
| Lupin Limited | 7.99% | ₹ 663.87 | Pharmaceuticals |
| Divi's Laboratories Limited | 6.56% | ₹ 545.21 | Pharmaceuticals |
| Dr. Reddy's Laboratories Limited | 5.81% | ₹ 482.33 | Pharmaceuticals |
| Cipla Limited | 5.67% | ₹ 471.20 | Pharmaceuticals |
| Apollo Hospitals Enterprise Limited | 5.17% | ₹ 429.24 | Hospitals & Medical Services |
| MedPlus Health Services Limited | 3.70% | ₹ 307.45 | Pharmaceuticals |
| Max Healthcare Institute Limited | 3.49% | ₹ 290.25 | Hospitals & Medical Services |
| Vijaya Diagnostic Centre Limited | 3.49% | ₹ 289.97 | Hospitals & Medical Services |
| Ajanta Pharma Limited | 3.41% | ₹ 283.32 | Pharmaceuticals |
| Sai Life Sciences Limited | 3.07% | ₹ 255.13 | Pharmaceuticals |
| Mankind Pharma Limited | 3.06% | ₹ 254.25 | Pharmaceuticals |
| GlaxoSmithKline Pharmaceuticals Limited | 2.83% | ₹ 234.85 | Pharmaceuticals |
| IPCA Laboratories Limited | 2.51% | ₹ 208.66 | Pharmaceuticals |
| Aurobindo Pharma Limited | 2.50% | ₹ 207.79 | Pharmaceuticals |
| Abbott India Limited | 2.37% | ₹ 196.82 | Pharmaceuticals |
| Alkem Laboratories Limited | 2.20% | ₹ 182.54 | Pharmaceuticals |
| Thyrocare Technologies Limited | 2.08% | ₹ 172.90 | Hospitals & Medical Services |
| Dr. Lal Path Labs Limited | 2.05% | ₹ 170.54 | Hospitals & Medical Services |
| JB Chemicals & Pharmaceuticals Limited | 1.98% | ₹ 164.21 | Pharmaceuticals |
| Pfizer Limited | 1.94% | ₹ 161.10 | Pharmaceuticals |
| Narayana Hrudayalaya Limited | 1.82% | ₹ 150.85 | Hospitals & Medical Services |
| Gland Pharma Limited | 1.76% | ₹ 145.88 | Pharmaceuticals |
| Emcure Pharmaceuticals Limited | 1.31% | ₹ 108.63 | Pharmaceuticals |
| Suraksha Diagnostic Limited | 1.27% | ₹ 105.77 | Hospitals & Medical Services |
| Fortis Healthcare Limited | 1.25% | ₹ 104.06 | Hospitals & Medical Services |
| Sanofi Consumer Healthcare India Limited | 1.15% | ₹ 95.92 | Chemicals - Speciality |
| Sanofi India Limited | 1.10% | ₹ 91.31 | Pharmaceuticals |
| Biocon Limited | 1.04% | ₹ 86.51 | Pharmaceuticals |
| Syngene International Limited | 0.96% | ₹ 79.52 | Pharmaceuticals |
| Anthem Biosciences Limited | 0.89% | ₹ 74.23 | Pharmaceuticals |
| Akums Drugs and Pharmaceuticals Limited | 0.89% | ₹ 73.97 | Pharmaceuticals |
| AstraZeneca Pharma India Limited | 0.67% | ₹ 55.37 | Pharmaceuticals |
| Indoco Remedies Limited | 0.45% | ₹ 37.12 | Pharmaceuticals |
| Triparty Repo | 0.34% | ₹ 28 | Others |
| Concord Biotech Limited | 0.16% | ₹ 13.64 | Pharmaceuticals |
Returns
| Annualised returns | ||||
|---|---|---|---|---|
| 9M | 1Y | 2Y | 3Y | |
| Fund returns | -13.05% | -5.75% | -2.49% | 11.73% |
| Category returns | -7.38% | 1.10% | 4.40% | 20.04% |
Fund Objective
The primary investment objective of the scheme is to seek to generate continuous returns by investing in equity and equity related or fixed-income securities of Pharma and other associated companies.
AMC Details
Name
Nippon Life India Asset Management Ltd.
Date of Incorporation
30 Jun 1995
CEO
Mr. Sundeep Sikka
CIO
Mr. Amit Tripathi Mr. Sailesh Raj Bhan
Type
Foreign
Address
4th Floor, Tower A,
Peninsula Business Park,
Ganapatrao Kadam Marg,
Lower Parel (W), Mumbai, Maharashtra, India - 400013
Website
https://www.nipponindiamf.com
Email
Top Funds from Equity - Sectoral/Thematic
|
Scheme Name
|
NAV
|
Returns
1Y
3Y
5Y
|
AUM (Cr)
|
Expense Ratio
|
Risk Meter
|
||
|---|---|---|---|---|---|---|---|
|
Axis Quant Fund
Diversified
Regular
|
₹14.17 | -3.21% | 33.05% | 0.00% | ₹882 | 2.25% |
Very High
|
|
Axis Quant Fund
Diversified
Regular
|
₹14.17 | -3.21% | 33.05% | 0.00% | ₹882 | 2.25% |
Very High
|
|
Axis Quant Fund
Diversified
Regular
|
₹14.17 | -3.21% | 33.05% | 0.00% | ₹882 | 2.25% |
Very High
|
|
SBI Technology Opportunities Fund
Sector
Regular
|
₹110.58 | -6.78% | 32.14% | 68.19% | ₹4,273 | 1.92% |
Very High
|
|
SBI Technology Opportunities Fund
Sector
Regular
|
₹110.58 | -6.78% | 32.14% | 68.19% | ₹4,273 | 1.92% |
Very High
|
|
SBI Technology Opportunities Fund
Sector
Regular
|
₹183.63 | -6.78% | 32.14% | 68.18% | ₹4,273 | 1.92% |
Very High
|
|
HDFC Banking & Financial Services Fund - Direct Plan
Sector
Direct
|
₹14.90 | 4.00% | 31.81% | 0.00% | ₹4,510 | 0.80% |
Very High
|
|
HDFC Banking & Financial Services Fund - Direct Plan
Sector
Direct
|
₹14.90 | 4.00% | 31.81% | 0.00% | ₹4,510 | 0.80% |
Very High
|
|
DSP Quant Fund - Direct Plan
Largecap
Direct
|
₹20.71 | -0.11% | 31.80% | 44.78% | ₹838 | 0.55% |
Very High
|
|
HSBC Infrastructure Fund
Sector
Regular
|
₹31.33 | -7.57% | 31.57% | 70.85% | ₹2,300 | 2.06% |
Very High
|
Top Funds from Nippon Life India Asset Management Ltd.
|
Scheme Name
|
NAV
|
Returns
1Y
3Y
5Y
|
AUM (Cr)
|
Expense Ratio
|
Risk Meter
|
||
|---|---|---|---|---|---|---|---|
|
Nippon India Value Fund
Diversified
Regular
|
₹37.97 | -8.46% | 33.01% | 48.24% | ₹9,034 | 1.82% |
Very High
|
|
Nippon India Value Fund
Diversified
Regular
|
₹37.97 | -8.46% | 33.01% | 48.24% | ₹9,034 | 1.82% |
Very High
|
|
Nippon India Nifty 50 Value 20 Index Fund
Index
Regular
|
₹17.06 | -4.12% | 32.10% | 65.07% | ₹1,021 | 0.78% |
Very High
|
|
Nippon India Nifty 50 Value 20 Index Fund
Index
Regular
|
₹17.06 | -4.12% | 32.10% | 65.07% | ₹1,021 | 0.78% |
Very High
|
|
Nippon India Nifty 50 Value 20 Index Fund
Index
Regular
|
₹17.06 | -4.12% | 32.10% | 65.07% | ₹1,021 | 0.78% |
Very High
|
|
Nippon India Multi Cap Fund
Diversified
Regular
|
₹53.57 | -5.95% | 30.91% | 63.43% | ₹50,820 | 1.49% |
Very High
|
|
Nippon India Multi Cap Fund
Diversified
Regular
|
₹53.57 | -5.95% | 30.91% | 63.43% | ₹50,820 | 1.49% |
Very High
|
|
Nippon India ELSS Tax Saver Fund - Direct Plan
ELSS
Direct
|
₹41.59 | -4.61% | 30.23% | 57.36% | ₹14,959 | 1.03% |
Very High
|
|
Nippon India ELSS Tax Saver Fund - Direct Plan
ELSS
Direct
|
₹41.59 | -4.61% | 30.23% | 57.36% | ₹14,959 | 1.03% |
Very High
|
|
Nippon India Vision Large & Mid Cap Fund - Direct Plan
Largecap
Direct
|
₹63.15 | -7.36% | 29.64% | 46.71% | ₹6,963 | 1.12% |
Very High
|
FAQs
What is the current NAV of Nippon India Pharma Fund Regular IDCW?
The current Net Asset Value (NAV) of Nippon India Pharma Fund Regular IDCW is ₹104.79 as of 02 Apr 2026. NAV represents the per-unit market value of the fund and is updated daily based on the closing prices of the underlying securities.
What is the fund size (AUM) of Nippon India Pharma Fund Regular IDCW?
The Assets Under Management (AUM) of Nippon India Pharma Fund Regular IDCW is ₹8,306.35 Crores. AUM indicates the total market value of assets managed by the fund and reflects investor confidence and fund popularity.
What are the historical returns of Nippon India Pharma Fund Regular IDCW?
Nippon India Pharma Fund Regular IDCW has delivered returns of -5.75% (1 Year), 11.73% (3 Year), 7.40% (5 Year). Past performance does not guarantee future results, and investors should consider their risk appetite before investing.
What is the risk level of Nippon India Pharma Fund Regular IDCW?
Nippon India Pharma Fund Regular IDCW has a risk rating of 'Very High' as per the SEBI Riskometer. This indicates the fund is suitable for very aggressive investors comfortable with significant market volatility. Investors should align their investment choices with their personal risk tolerance and financial goals.
What is the minimum investment amount for Nippon India Pharma Fund Regular IDCW?
The minimum lumpsum investment required for Nippon India Pharma Fund Regular IDCW is ₹5,000. The fund also offers SIP (Systematic Investment Plan) option starting from as low as ₹100, making it accessible for regular investments. This allows investors to start their mutual fund journey with a manageable amount.
Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article
-
The Best Way To Build A Mutual Fund Portfolio In Your 20s, 30s And 40s -
How To Gift Mutual Funds To Children: Rules, Tax Implications And Process Explained -
How to Position Portfolio Amid Global Tensions, Rising Gold,Silver ETF Inflows? Navi CEO Aditya Mulki Explains -
NPS vs Mutual Funds For Retirement: Which Investment Option Offers Better Growth, Tax Benefits And Stability? -
Big Shake-Up in Mutual Funds! SEBI Scraps Solution Funds, Introduces Life-Cycle Category | 5 Changes Explained -
Selling Mutual Funds? Here’s How You Can Save Capital Gains Tax Under Section 54F -
What Are Multi-Cap Mutual Funds? Single Fund Exposure to Large, Mid and Small-Cap Stocks; Know Details -
Can UAE-Based NRIs Invest In Indian Mutual Funds? Rules, Taxes And DTAA Explained -
What Is A Balanced Advantage Fund (BAF) And How Does It Work? -
Are Retirement Mutual Funds The Right Choice For Long-Term Investment Planning?
Top Mutual Fund House in India
Notifications
Settings
Clear Notifications
Notifications
Use the toggle to switch on notifications
-
Block for 8 hours
-
Block for 12 hours
-
Block for 24 hours
-
Don't block
Stay Informed.
Get news and videos anytime and anywhere.
Sign in with Google By signing in, you agree to our Terms and Privacy Policy
Gender
Select your Gender
- Male
- Female
- Others
Age
Select your Age Range
- Under 18
- 18 to 25
- 26 to 35
- 36 to 45
- 45 to 55
- 55+